I like the prediction game, even though nobody won last time bc we still have yet to see any DMC efficacy recommendation. I will predict 1 PR, probably at the end of next week.
My logic: NW has had the 8-week data on the low-dose cohort for a while now, but it was not impressive. If it were, they would have announced it before their offering. The middle-dose subjects have only a few data points past the 8-week mark (we read about one), but two or more data points may be collected by next week. Maybe that gives a total of 8 or more to report on, and even NW is on the edge of their seat hoping for highlights.
For exemptions and news from Germany, I think they would have to report this news when it is available (or as soon as they can translate it into English), so I doubt we will hear anything about that. I believe they forced their own hand by prematurely stamping this huge presence at ASCO, mainly because LP is very bad at timeline estimates. They will not have most of the goals met from their estimates, such as full enrollment in L and full enrollment in D with substantial data. I would love to see the PR campaign begin, but I just don't think they have enough to say yet...
Speaking of full enrollment in L, shouldn't that be coming up soon along with the 88th event? Patience, patience... patients!
Market Data 
Markets 
AI
